Ezogabine
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 314222

CAS#: 150812-12-7 (free base)

Description: Ezogabine is an anticonvulsant used as an adjunctive treatment for partial epilepsies in treatment-experienced adult patients. The drug was developed by Valeant Pharmaceuticals and GlaxoSmithKline. Ezogabine works primarily as a potassium channel opener—that is, by activating a certain family of voltage-gated potassium channels in the brain. This mechanism of action is unique among antiepileptic drugs, and may hold promise for the treatment of other neurologic conditions, including migraine, tinnitus and neuropathic pain. (Source: http://en.wikipedia.org/wiki/Retigabine).


Price and Availability

Size
Price

10mg
USD 60
100mg
USD 250
1g
USD 950
10g
USD 3650
Size
Price

25mg
USD 90
200mg
USD 350
2g
USD 1450
20g
USD 4950
Size
Price

50mg
USD 150
500mg
USD 550
5g
USD 2650
50g
Ask price

Ezogabine, purity > 98%, is in stock. The same day shipping out after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 314222
Name: Ezogabine
CAS#: 150812-12-7 (free base)
Chemical Formula: C16H18FN3O2
Exact Mass: 303.13831
Molecular Weight: 303.33
Elemental Analysis: C, 63.35; H, 5.98; F, 6.26; N, 13.85; O, 10.55


Synonym: D23129; D-23129; D 23129; GKE 841; GW 582892X; WAY 143841; Ezogabine; Retigabine; Trobalt; Potiga.

IUPAC/Chemical Name: ethyl N-[2-amino-4-[(4-fluorophenyl)methylamino]phenyl]carbamate

InChi Key: QUAXPMCGRPZNEG-UHFFFAOYSA-N

InChi Code: InChI=1S/C16H18FN3O2/c1-3-22-16(21)19-15-9-8-13(10-14(15)18)20(2)12-6-4-11(17)5-7-12/h4-10H,3,18H2,1-2H3,(H,19,21)

SMILES Code: O=C(OCC)NC1=CC=C(N(C2=CC=C(F)C=C2)C)C=C1N


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Certificate of Analysis:

Safety Data Sheet (MSDS):

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO.

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


Additional Information

Related CAS#
CAS#150812-12-7 (free base);
CAS#150812-13-8 (2HCl).


References

 1: Faulkner MA, Burke RA. Safety profile of two novel antiepileptic agents approved for the treatment of refractory partial seizures: ezogabine (retigabine) and perampanel. Expert Opin Drug Saf. 2013 Nov;12(6):847-55. doi: 10.1517/14740338.2013.823399. Epub 2013 Jul 25. Review. PubMed PMID: 23883095.

2: Amabile CM, Vasudevan A. Ezogabine: a novel antiepileptic for adjunctive treatment of partial-onset seizures. Pharmacotherapy. 2013 Feb;33(2):187-94. doi: 10.1002/phar.1185. Review. PubMed PMID: 23386597.

3: Yamada M, Welty TE. Ezogabine: an evaluation of its efficacy and safety as adjunctive therapy for partial-onset seizures in adults. Ann Pharmacother. 2012 Oct;46(10):1358-67. doi: 10.1345/aph.1R153. Epub 2012 Sep 18. Review. PubMed PMID: 22991134.

4: Verma A, Kumar R, Kumar M. Ezogabine: development and role in the management of epileptic seizures. Mini Rev Med Chem. 2013 Apr 1;13(5):697-705. Review. PubMed PMID: 22931529.

5: Splinter MY. Ezogabine (retigabine) and its role in the treatment of partial-onset seizures: a review. Clin Ther. 2012 Sep;34(9):1845-56.e1. doi: 10.1016/j.clinthera.2012.07.009. Epub 2012 Aug 21. Review. PubMed PMID: 22917854.

6: Hopkins CR. ACS chemical neuroscience molecule spotlight on Potiga (Ezogabine). ACS Chem Neurosci. 2012 Aug 15;3(8):632. doi: 10.1021/cn3000789. Review. PubMed PMID: 22896808; PubMed Central PMCID: PMC3419453.

7: Orhan G, Wuttke TV, Nies AT, Schwab M, Lerche H. Retigabine/Ezogabine, a KCNQ/K(V)7 channel opener: pharmacological and clinical data. Expert Opin Pharmacother. 2012 Aug;13(12):1807-16. doi: 10.1517/14656566.2012.706278. Epub 2012 Jul 12. Review. PubMed PMID: 22783830.

8: Brickel N, Gandhi P, VanLandingham K, Hammond J, DeRossett S. The urinary safety profile and secondary renal effects of retigabine (ezogabine): a first-in-class antiepileptic drug that targets KCNQ (K(v)7) potassium channels. Epilepsia. 2012 Apr;53(4):606-12. doi: 10.1111/j.1528-1167.2012.03441.x. Epub 2012 Mar 16. Review. PubMed PMID: 22428574.

9: Gunthorpe MJ, Large CH, Sankar R. The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy. Epilepsia. 2012 Mar;53(3):412-24. doi: 10.1111/j.1528-1167.2011.03365.x. Epub 2012 Jan 5. Review. PubMed PMID: 22220513.

10: Chung SS, Kelly K, Schusse C. New and Emerging Treatments for Epilepsy: Review of Clinical Studies of Lacosamide, Eslicarbazepine Acetate, Ezogabine, Rufinamide, Perampanel, and Electrical Stimulation Therapy. J Epilepsy Res. 2011 Dec 30;1(2):35-46. eCollection 2011 Dec. Review. PubMed PMID: 24649444; PubMed Central PMCID: PMC3952328.